No Data
Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Autolus Therapeutics Analyst Ratings
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Redburn Atlantic Initiates Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $13
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
